[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Greater Poland Cancer Centre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":75},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100593813","subclinical-monitoring-of-lymphatic-function-in-oncology-patients-for-lymphoedema-prevention-oncolymph-100593813",false,"NCT07011316","Subclinical Monitoring of Lymphatic Function in Oncology Patients for Lymphoedema Prevention (ONCOLYMPH)","Subclinical Assessment and Monitoring of Lymphatic System Function in Oncology Patients as Part of Physiotherapeutic Prevention of Limb Lymphoedema","ONCOLYMPH","Inclusion Criteria:\n\n* admission to the Greater Poland Cancer Centre for treatment in one of the departments participating in the study,\n* age ≥ 18 years,\n* ability to balance independently in a standing position for 30 seconds,\n* obtaining the patient's written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* age ≤ 18 years,\n* cardiac arrhythmia,\n* pacemakers or other implanted electronic devices,\n* history of external defibrillation,\n* pregnancy,\n* critical limb ischaemia,\n* advanced heart failure (NYHA III and IV0),\n* symptoms of deep vein thrombosis,\n* uncompensated heart, kidney or thyroid failure,\n* peripheral nerve damage,\n* presence of psychiatric disorders that preclude informed consent or limit appropriate co-operation of the patient,\n* lack of informed consent from the patient to participate in the study.","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","Lymphoedema, a chronic condition caused by the accumulation of protein-rich fluid in the intercellular spaces due to impaired lymphatic function, is a common complication in cancer patients. It can lead to visible swelling, discomfort, and mobility issues, but most frequently affects the limbs. This condition not only impacts patients physically but also has significant psychological consequences, including reduced quality of life, social stigma, and challenges with returning to daily activities.\n\nOncology patients are particularly at risk for developing lymphoedema due to factors such as lymphadenectomy, radiotherapy, and extensive surgical procedures. Up to 30% of breast cancer survivors develop lymphoedema, and it is also a common complication in patients treated for other cancers, such as those involving the cervix, vulva, prostate, and bladder. Despite the importance of early detection, diagnostic tools for assessing lymphatic dysfunction are often specialised and not suitable for routine screening in clinical practice.\n\nThe primary goal of this study is to explore the early signs of lymphatic dysfunction in cancer patients before evident clinical symptoms, with the aim of identifying individuals at risk of developing lymphoedema. This will provide valuable information that could guide early interventions and preventive measures to reduce the severity or even prevent the onset of lymphoedema. By focusing on early, subclinical dysfunction, the study seeks to contribute to improving both the clinical management of lymphatic complications and the overall quality of life for oncology patients. Regular monitoring and timely physiotherapy interventions could play a key role in enhancing recovery outcomes and reducing the long-term impact of lymphoedema.",[25],"Lymphoedema",[25,27,28,29],"Cancer","Prevention","bioimpedance spectroscopy","RECRUITING","2025-05-30",{"date":33,"type":34},"2025-06-08","ACTUAL",{"date":36,"type":34},"2025-01-01",{"date":38,"type":21},"2029-12-31",{"name":40,"class":41},"The Greater Poland Cancer Centre","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":42},"100494232","focal-salvage-brachytherapy-study-focasabra-100494232","NCT05715502","Focal Salvage Brachytherapy Study (FocaSaBra)","Assessment of the Toxicity of Focal Salvage Brachytherapy of Recurrent Prostate Cancer After Prior Radiotherapy - the Prospective Focal Salvage Brachytherapy Study (FocaSaBra)","FocaSaBra","Inclusion Criteria:\n\n* Histopathologically confirmed by biopsy (fusion mapping biopsy preferred) recurrence of prostate cancer after prior radical radiotherapy (brachytherapy, external beam radiotherapy alone or with brachytherapy boost, stereotaxic radiotherapy)\n* Localized tumor lesion assessed by MRI or in the case of MR contraindications with TRUS and CT\n* Exclusion of distant metastases using CT, MR, or PET imaging\n* PSA doubling time over six months\n* PSA value \\\u003C10 ng \u002F ml\n* No anti-androgen treatment in the year prior\n* Dysuria on the IPSS (International Prostate Symptom Score) ≤ 20 points\n* General condition according to the WHO scale ≤ 2\n* Signing informed consent to participate in the study\n\nExclusion Criteria:\n\n* PSA value\\> 10ng \u002F ml\n* General condition according to the WHO scale\\> 2\n* Dysuria on the IPSS scale\\> 20 points\n* PSA doubling time \\\u003C6 months\n* Inability to discontinue anticoagulants.\n* An active urinary tract infection.\n* Contraindications to general anesthesia\n* Active inflammatory bowel diseases.\n* Second active cancer or treatment with completion less than 3 years earlier, except for low-stage skin cancer\n* Estimated Survival \\\u003C5 years","MALE",{"count":53,"type":21},100,"INTERVENTIONAL",[56],"NA","The aim of this prospective phase II study is to evaluate the toxicity of salvage partial (focal) prostate brachytherapy in patients after prior radiotherapy (standard teleradiotherapy with \u002F without brachytherapy, hypofractionated, self-reactive HDR \u002F LDR brachytherapy) with local recurrence on the part of the prostate gland.",[59],"Prostate Cancer",[61,62,63,64,65,66],"recurrence","prostate cancer","brachytherapy","focal treatment","salvage treatment","radiotherapy","2025-04-28",{"date":69,"type":34},"2025-04-30",{"date":71,"type":34},"2022-05-01",{"date":73,"type":21},"2028-12-31",{"name":40,"class":41},""]